
Celularity Inc. - Class A Common Stock
Aktie · US1511902041 · CELU (XNAS)
2,07 USD
06.06.2025 19:59
Aktuelle Kurse von Celularity Inc. - Class A Common Stock
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung |
---|---|---|---|---|---|
![]() NASDAQ |
CELU
|
USD
|
06.06.2025 19:59
|
2,07 USD
| 1,92 USD
+7,81 %
|
Performance
Heute | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -6,33 % | 21,05 % | 61,72 % | -10,78 % | -36,31 % | -97,91 % |
Firmenprofil zu Celularity Inc. - Class A Common Stock Aktie
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Unternehmensdaten
Name Celularity Inc. - Class A Common Stock
Firma Celularity Inc.
Symbol CELU
Website
https://www.celularity.com
Heimatbörse
NASDAQ

ISIN US1511902041
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Robert Joseph Hariri M.D., Ph.D.
Marktkapitalisierung 37 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,1 T
Adresse 170 Park Avenue, 07932 Florham Park
IPO Datum 2019-08-08
Kennungs-Wechsel
Datum | Von | Zu |
---|---|---|
19.07.2021 | GXGX | CELU |
Ticker Symbole
Name | Symbol |
---|---|
NASDAQ | CELU |
Weitere Aktien
Investoren die Celularity Inc. - Class A Common Stock die halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.